|
|
|
This is the preliminary program for the 2007 Joint Statistical
Meetings in Salt Lake City, Utah.
|
|
|
The views expressed here are those of the individual authors and not necessarily those of the ASA or its board, officers, or staff. Back to main JSM 2007 Program page |
= Applied Session,
= Theme Session,
= Presenter
378
|
Wed, 8/1/07, 8:30 AM - 10:20 AM | CC-355 D |
| Bayesian Approaches in Drug Development - Contributed - Papers | ||
|
Biopharmaceutical Section |
||
| Chair(s): Susan Portugal, Wyeth | ||
| 8:35 AM |
A Revisit to Sample Size Computation —  Ruoyong Yang, Pfizer Inc.
|
|
| 8:50 AM |
Joint Exploration of Haplotype Information and High-Order SNP-Phenotype Associations via Gibbs Sampling — Jing Zhao, Merck & Co., Inc.
|
|
| 9:05 AM |
Using the Bayesian Approach for Pharmaceutical Process Optimization — Aili Cheng, GlaxoSmithKline; John Peterson, GlaxoSmithKline; Younan Chen, GlaxoSmithKline; Gregory Stockdale, GlaxoSmithKline
|
|
| 9:20 AM |
Bayesian Spines To Infer Population Mean and Tolerance Region from Multivariate Longitudinal Data — Qianqiu Li, Wyeth; Yonggang Zhao, Wyeth
|
|
| 9:35 AM |
Bayesian Hierarchical Models for Detecting Safety Signals in Clinical Trials — Hong A. Xia, Amgen Inc.; Haijun Ma, Amgen Inc.
|
|
| 9:50 AM |
Controlled Bayesian Optimal Designs for Dose-Response Studies — Wei Zhu, State University of New York at Stony Brook; Jiaqiao Hu, State University of New York at Stony Brook; Weng-Kee Wong, University of California, Los Angeles
|
|
| 10:05 AM |
A Bayesian Approach to Utilizing Prior Data in New Drug Development — Todd Coffey, Amylin Pharmaceuticals, Inc.; Larry Z. Shen, Amylin Pharmaceuticals, Inc.; Wei Deng, Amylin Pharmaceuticals, Inc.
|
|
|
JSM 2007
For information, contact jsm@amstat.org
or phone (888) 231-3473. If you have questions about the Continuing Education program,
please contact the Education Department. |